Personal information

Other IDs

ResearcherID: Q-6737-2017

Activities

Collapse all

Employment (4)

Universitätsklinikum Freiburg: Freiburg, Baden-Württemberg, DE

2016-05-19 to present (Radiation therapy)
Employment
Source: Self-asserted source
Per Lund

Institut de Genetique et de Biologie Moleculaire et Cellulaire Biologie et Génomique structurale: Strasbourg, Alsace, FR

2006-09-01 to 2012-01-31 | Postdoc (Génomique fonctionnelle et cancer)
Employment
Source: Self-asserted source
Per Lund

Charité Universitätsmedizin Berlin: Berlin, Berlin, DE

2001-04-01 to 2006-01-31 | Postdoc (Molecular Tumour Pathology)
Employment
Source: Self-asserted source
Per Lund

Uniklinik Köln: Köln, Nordrhein-Westfalen, DE

1998-08-01 to 2001-03-31 | PhD Student (Pathology)
Employment
Source: Self-asserted source
Per Lund

Works (11)

A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement.

Lab on a chip
2017-12 | Journal article
DOI: 10.1039/c7lc00832e
PMID: 29211089
Source: Self-asserted source
Per Lund via Europe PubMed Central

Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.

Molecular cancer therapeutics
2011-09 | Journal article
DOI: 10.1158/1535-7163.mct-11-0140
PMID: 21697397
Source: Self-asserted source
Per Lund via Europe PubMed Central

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.

PLoS genetics
2010-12 | Journal article
DOI: 10.1371/journal.pgen.1001231
PMID: 21170361
PMC: PMC2996331
Source: Self-asserted source
Per Lund via Europe PubMed Central

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

International journal of cancer
2009-10 | Journal article
DOI: 10.1002/ijc.24557
PMID: 19569244
Source: Self-asserted source
Per Lund via Europe PubMed Central

Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.

Advances in enzyme regulation
2007 | Journal article
DOI: 10.1016/j.advenzreg.2006.12.001
PMID: 17335873
Source: Self-asserted source
Per Lund via Europe PubMed Central

Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer.

The Journal of pathology
2007-03 | Journal article
DOI: 10.1002/path.2132
PMID: 17236181
Source: Self-asserted source
Per Lund via Europe PubMed Central

Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.

Oncogene
2006-08 | Journal article
DOI: 10.1038/sj.onc.1209502
PMID: 16568090
Source: Self-asserted source
Per Lund via Europe PubMed Central

Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells.

Oncogene
2004-06 | Journal article
DOI: 10.1038/sj.onc.1207585
PMID: 15064704
Source: Self-asserted source
Per Lund via Europe PubMed Central

Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II.

Cancer letters
2004-03 | Journal article
DOI: 10.1016/j.canlet.2003.10.018
PMID: 15019164
Source: Self-asserted source
Per Lund via Europe PubMed Central

Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis.

British journal of cancer
2001-09 | Journal article
DOI: 10.1054/bjoc.2001.1963
PMID: 11531255
PMC: PMC2364116
Source: Self-asserted source
Per Lund via Europe PubMed Central

Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms.

Mutation research
1998-09 | Journal article
DOI: 10.1016/s0027-5107(98)00135-3
PMID: 9748564
Source: Self-asserted source
Per Lund via Europe PubMed Central
How many people are using ORCID?